IDH1 and astrocytoma (excluding glioblastoma): For example, the IDH1-vac, an IDH1 (R132H)-specific peptide vaccine, met its primary safety endpoint in a phase I trial involving 33 grade 3 and 4 IDH1(R132H)+ astrocytomas patients.